EGFR and non-small cell lung carcinoma: In conclusion, combinatorial targeting of both ligands (VEGFA and VEGFC) or their receptors (VEGFR2 and KDR) may enhance the clinical benefit of ABCP in EGFR‐TKI‐resistant NSCLC patients.